Tumour necrosis factor beta gene polymorphisms in myasthenia gravis

Citation
G. Zelano et al., Tumour necrosis factor beta gene polymorphisms in myasthenia gravis, EUR J IMM, 25(6), 1998, pp. 403-408
Citations number
44
Categorie Soggetti
Immunology
Journal title
EUROPEAN JOURNAL OF IMMUNOGENETICS
ISSN journal
09607420 → ACNP
Volume
25
Issue
6
Year of publication
1998
Pages
403 - 408
Database
ISI
SICI code
0960-7420(199812)25:6<403:TNFBGP>2.0.ZU;2-5
Abstract
Genetic analyses indicate that genes within the major histocompatibility co mplex (MHC) can be involved in susceptibility to autoimmune disease. To inv estigate the role of the tumour necrosis factor beta (TNFB) gene in myasthe nia gravis (MG) susceptibility, we analysed an NcoI polymorphism within the TNFB gene in 63 MG patients and 93 healthy individuals. When patients were subdivided according to thymic pathology, we found differences between MG patients with thymic hyperplasia and thymoma versus controls. In MG patient s with thymic hyperplasia we found a positive association with the TNFB*1 a llele [Relative risk (RR): 2.6; P<0.001] and phenotype (RR: 1.8; P<0.005) a nd a negative association with the TNFB*2/2 genotype (RR: 0.2; P<0.001) whe n compared to the controls. On the other hand, in MG patients with thymoma we found a positive association with the TNFB*2/2 genotype (RR: 5.6; P<0.01 ) and a negative association with the TNFB*1 allele (RR: 0.3; P<0.05) and * 1/2 genotype (RR: 0.2; P<0.01). These data suggest that the two different f orms of MG can have different pathogenesis and that the TNFB gene could inf luence susceptibility to MG.